meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 2nd line (L2)
2
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus SoC
avelumab based treatment
avelumab alone
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs gemcitabine plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
vs non active control
vs BSC
vs no additional treatment
vs no control (uncontrolled study)
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
nivolumab alone
title
placebo
title
CheckMate 274 (all population), 2017 NCT02632409 MIBC - NA - all population 353/356
CheckMate 274 (PDL1>1%), 2017 NCT02632409 MIBC - NA - PDL1 positive 140/142
Pathology:
MIBC - NA - all population;
MIBC - NA - PDL1 positive;
MIBC - NA - all population
MIBC - NA - PDL1 positive
CheckMate 274 (all population), 2017
CheckMate 274 (PDL1>1%), 2017
nivolumab alone
2
T1
T1
placebo
0
T0
T0